

Change in number of shares and votes in SynAct Pharma

During the month of December, the number of shares and votes in SynAct Pharma AB (publ) have increased due to a directed issue of shares which was resolved upon by the board of directors on December 12, 2022, pursuant to the authorization granted by the annual general meeting on May 20, 2022.

Through the direct share issue, carried out in December 2022, the number of outstanding shares and votes has increased by 1,277,954, from 28,370,503 to 29,648,457. The share capital has increased by SEK 159,744.25, from SEK 3,546,312.875 to SEK 3,706,057.125.

As of December 30, 2022, the total number of shares and votes in SynAct Pharma AB amounts to 29,648,457 shares and votes.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: joo@synactpharma.com

Patrik Renblad

CFO, SynAct Pharma AB

Phone: +46 707 47 97 68

Mail: par@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2022-12-30 13:00 CET.

Attachments

[Change in number of shares and votes in SynAct Pharma](#)